Addressing the Public Health Effects of Opioid Medications September 9, 2026

Meeting | Mixed

• Date: September 9, 2026
• Time: 12:30 p.m. - 4:30 p.m. ET
• Location: Attend In Person or Online; Virtual: Via webcast; In Person: FDA White Oak Campus; 10903 New Hampshire Avenue; Building 31, Room 1503; Silver Spring, MD 20993; United States

---

Attend

View Agenda and Register

---

On September 9, 2026, the U.S. Food and Drug Administration, in partnership with the Reagan-Udall Foundation for the FDA (Foundation), will convene a hybrid meeting to hear public comments on perspectives regarding the use of opioid medications for the management of pain and addiction. The meeting will also feature a panel discussion with federal partners to discuss efforts to improve the management of pain and addiction.

Patients, family members/caregivers, healthcare providers, drug developers, and others are invited to share their interest in speaking either in person or virtually on the following topics:

1. Scientific evidence regarding conditions of use, safety concerns, or benefit-risk assessment (including consideration of the public health effects) of opioid medications
2. Input on FDA’s regulation of opioid medications
3. Additional actions that could be considered to address the public health effects of opioid medications

The deadline to request to present public comment is Thursday, August 27, 2026. Comments can be made by in-person and virtual attendees.  

This meeting is one of several engagement activities being conducted in collaboration with the Foundation in partial fulfillment of Section 112 of the SUPPORT for Patients and Communities Reauthorization Act of 2025 (H.R. 2483), “Assessment of Opioid Drugs and Actions.”